CSS LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

CSS LLC’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,500	Closed	-$312K	–	527
2017 Q4	$312K	Hold	3,500	–	–	0.02%	417
2017 Q3	$326K	Hold	3,500	–	–	0.02%	427
2017 Q2	$318K	Buy	+3,500	New	+$318K	0.02%	431
2017 Q1	–	Sell	-4,100	Closed	-$340K	–	640
2016 Q4	$340K	Hold	4,100	–	–	0.02%	416
2016 Q3	$379K	Hold	4,100	–	–	0.02%	429
2016 Q2	$319K	Hold	4,100	–	–	0.02%	476
2016 Q1	$338K	Buy	4,100 +100	+3%	+$8.14K	0.02%	419
2015 Q4	$419K	Hold	4,000	–	–	0.02%	401
2015 Q3	$421K	Buy	+4,000	New	+$534K	0.02%	431

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

CSS LLC's BMRN Position: Q2 2026 in Review

CSS LLC increased its BioMarin Pharmaceuticals (BMRN) stake by 41% in Q2 2026, buying an estimated $362K and bringing the position to 22,580 shares worth $1.29M. The position accounts for 0.05% of the portfolio, ranked #268.

CSS LLC first reported a position in BMRN in Q3 2016 and has held it in 11 quarters since. The position peaked at $1.3M in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

CSS LLC held 22,580 shares of BioMarin Pharmaceuticals worth $1.29M as of Q2 2026.
CSS LLC bought 6,600 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $362K.
BioMarin Pharmaceuticals made up 0.05% of CSS LLC's portfolio in Q2 2026, its #268 holding.
CSS LLC first reported a position in BioMarin Pharmaceuticals in Q3 2016 and has held it in 11 quarters since.
CSS LLC's BioMarin Pharmaceuticals position peaked at $1.3M in Q3 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on CSS LLC's 13F filing for Q2 2026, filed 14 Aug 2026.